Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ocugen, Inc.

NASDAQ: OCGN · Life Sciences · 10 alerts · CIK 1372299

Ocugen, Inc. stories on ALFA USA NewsRead the news →
Share price
$0.7730Close, Nov 16
Market cap
$262M
Shares outstanding
339.31MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ocugen, Inc. filings on SEC EDGAR ↗

8:31 AM ET 8-K
Licensing Deal

Ocugen Licensing Deal with Celairis Therapeutics Holdings Pty Ltd Worth $7.1M

Ocugen granted Celairis Therapeutics an exclusive license to commercialize its OCU400 gene therapy for retinitis pigmentosa in Australia, New Zealand, and ASEAN markets. Ocugen will receive up to $7.1 million in upfront and milestone payments, plus high single-digit royalties and 50% of gross profits from net sales. Ocugen retains sole manufacturing rights and expects to enter a formal supply agreement within 90 days.

Value
$7.1M
Counterparty
Celairis Therapeutics Holdings Pty Ltd
Term
20 years
9:44 AM ET 10-Q
Financial Results ▶ Call

Ocugen Q3 2026 Results: Net Loss of $3.6M, Loss Narrows

Ocugen, Inc. reported total assets of $108.1 million as of September 30, 2026, a significant increase from $43.5 million at the end of 2025, primarily driven by $59.6 million in new short-term investments. The company is currently advancing its Phase 3 trial for OCU400 and Phase 2/3 trial for OCU410ST while maintaining its status as a non-accelerated filer and smaller reporting company.

Key figure
Net loss $3.6M
8:29 AM ET 8-K
Financial Results

Ocugen Financial Results

Ocugen reported Q3 2026 financial results, highlighting a cash position of $84.6 million with an expected runway into 2028. The company advanced its gene therapy pipeline, including the initiation of the Phase 3 ArMaDa3 trial for OCU410 and receiving provisional approval for OCU400 in The Bahamas.

Term
Q3 2026

“With three Phase 3 modifier gene therapy programs underway, Ocugen is executing against a clear strategy of advancing our pipeline and leveraging strategic partnerships to expand global reach and potentially bring our therapies to patients worldwide.”

Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen

“As we demonstrated in the third quarter, we remain focused on executing key clinical and regulatory milestones, expanding our commercial opportunities, and maintaining a disciplined approach as we advance toward the anticipated OCU400 Phase 3 topline data early next year.”

Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.